Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy ; volume:43 ; number:1 ; day:26 ; month:6 ; year:2024 ; pages:1-16 ; date:12.2024
Journal of experimental & clinical cancer research ; 43, Heft 1 (26.6.2024), 1-16, 12.2024
- Urheber
-
Zheng, Bowen
Qian, Fengyuan
Wang, Xuehui
Wang, Yuying
Zhou, Baian
Fang, Lin
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-024-03085-w
- URN
-
urn:nbn:de:101:1-2409162100126.353555033995
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zheng, Bowen
- Qian, Fengyuan
- Wang, Xuehui
- Wang, Yuying
- Zhou, Baian
- Fang, Lin
- SpringerLink (Online service)
Ähnliche Objekte (12)
Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer
AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
Toosendanin, a late-stage autophagy inhibitor, sensitizes triple-negative breast cancer to irinotecan chemotherapy
Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2
Characterizing triple-negative breast cancer tumors
Triple-Negative Breast Cancer: Multimodality Appearance
PAK inhibitor FRAX486 decreases the metastatic potential of triple-negative breast cancer cells by blocking autophagy
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand